导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.37% | 2325/2676 |
| 近一周 | -2.87% | 2389/3004 |
| 近一月 | -6.89% | 2336/2984 |
| 近一季 | 1.13% | 446/2896 |
| 近半年 | -12.54% | 2098/2746 |
| 近一年 | -25.46% | 2352/2519 |
| 近两年 | 13.38% | 1682/1796 |
| 近三年 | -11.19% | 1213/1340 |
| 成立以来 | 0.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.56% 4236/4961 |
-15.68% 4692/5312 |
- - |
- - |
| 2025 | 15.48% 2540/4813 |
19.07% 119/3635 |
-2.79% 3378/4076 |
15.94% 2752/4524 |
-13.96% 4322/4813 |
| 2024 | 7.43% 1661/3463 |
-4.31% 1637/2808 |
-4.79% 1556/3014 |
28.36% 191/3129 |
-8.13% 2833/3463 |
| 2023 | -22.38% 1928/2656 |
-4.98% 2127/2280 |
-5.26% 1411/2385 |
-5.56% 1337/2515 |
-8.70% 2305/2655 |
| 2022 | -12.94% 308/2207 |
-20.94% 1591/1919 |
19.70% 77/2016 |
-17.78% 1644/2113 |
11.88% 137/2208 |
| 2021 | -16.64% 1165/1822 |
-1.35% 476/1255 |
10.20% 489/1330 |
-14.36% 1368/1466 |
-10.46% 1604/1822 |
| 2020 | 48.54% 183/1250 |
-13.02% 916/1028 |
30.18% 62/1067 |
11.67% 431/1164 |
17.47% 123/1184 |
| 2019 | - - |
- - |
- - |
0.30% 534/850 |
9.89% 178/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 泰康港股通大消费指数A VS. 长安沪深300非周期A(740101) |